Publications by authors named "Joshua Sammon"
Article Synopsis
- The standard treatment for severe hemophilia A is lifelong prophylaxis with factor VIII concentrate, which incurs significant healthcare costs varying widely among patients.
- A study analyzed claims data from 411 adult males with hemophilia A treated between January 2013 and September 2019 to estimate their average annual healthcare expenses.
- Results showed a high per-patient mean cost of $654,571, with over 96% attributed to factor VIII concentrate; costs varied depending on the type of concentrate used, with extended half-life formulations being the most expensive.
Health insurance coverage and switching among people with hemophilia A in the United States.
J Manag Care Spec Pharm
February 2022
Article Synopsis
- Hemophilia A (HA) poses significant economic challenges due to costs related to ongoing treatment, monitoring, and managing associated health issues; gene therapies could help reduce these costs in the long term but face coverage hurdles from the fragmented US insurance system.
- A study analyzed data from adults with severe hemophilia A to understand insurance coverage, revealing that over half had commercial insurance and most did not frequently switch coverage types.
- Among those with commercial insurance, a high percentage maintained the same provider over a lengthy follow-up period, indicating stability in coverage despite the potential for insurance switching.
Standard of care for bleed prevention in patients with severe congenital hemophilia A is continuous prophylaxis with factor VIII (FVIII), typically administered intravenously 2-3 times per week in the home setting. Nonfactor prophylaxis and gene therapy are emerging novel prophylaxis strategies for hemophilia A, and it is important to compare their health economics with that of FVIII prophylaxis. Current data on resource utilization and costs in the adult hemophilia A prophylaxis population are limited, and a structured approach to analyze annual costs in these patients using administrative claims data has not been previously reported.
View Article and Find Full Text PDF